泌尿系统肿瘤PD-L1的检测与判读  

Detection and interpretation of PD-L1 in urologic neoplasms

作　　者：龚苗子 贺慧颖 Gong Miaozi;He Huiying(Department of Pathology,The University of Hong Kong-Shenzhen Hospital,Shenzhen518053,China)

机构地区：[1]香港大学深圳医院病理科,深圳518053 [2]北京大学医学部病理学系/北京大学第三医院病理科,北京100191

出　　处：《中华病理学杂志》2025年第1期11-15,共5页Chinese Journal of Pathology

摘　　要：针对PD-1/PD-L1的免疫检查点抑制剂逐渐应用于晚期泌尿系统肿瘤的治疗实践,免疫组织化学检测PD-L1表达是筛选免疫治疗适宜人群和预测疗效的最常用方法。本文总结了泌尿系统肿瘤(主要为尿路上皮癌)PD-L1检测的应用现状、不同抗体检测方法及判读结果时的注意事项、常见问题和解决方案。Immune checkpoint inhibitors targeting PD-1/PD-L1 are gradually being applied in the treatment of advanced urinary system tumors.Immunohistochemical analysis of PD-L1 expression is the most popular method for screening suitable patients for immunotherapy and predicting therapeutic efficacy.The current application status of PD-L1 detection for urinary system tumors(mainly urothelial carcinoma),methods of the different antibody tests and the precautions,challenges and solutions in the interpretation of immunostaining were summarized in this review.

关 键 词：泌尿系肿瘤 免疫组织化学 PD-L1 

分 类 号：R737[医药卫生—肿瘤]